These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37175393)

  • 1. Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome.
    Casiraghi F; Todeschini M; Podestà MA; Mister M; Ruggiero B; Trillini M; Carrara C; Diadei O; Villa A; Benigni A; Remuzzi G
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for nephrotic syndrome in children.
    Iijima K; Sako M; Nozu K
    Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
    Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
    DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
    BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
    Inoki Y; Kamei K; Nishi K; Sato M; Ogura M; Ishiguro A
    Pediatr Nephrol; 2022 May; 37(5):1057-1066. PubMed ID: 34606002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic rituximab administration in children with complicated nephrotic syndrome.
    Okutsu M; Kamei K; Sato M; Kanamori T; Nishi K; Ishiwa S; Ogura M; Sako M; Ito S; Ishikura K
    Pediatr Nephrol; 2021 Mar; 36(3):611-619. PubMed ID: 32995922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
    Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
    Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology.
    George J; Alex S; Thomas ETA; Gracious N; Vineetha NS; Kumar S
    Kidney360; 2020 May; 1(5):359-367. PubMed ID: 35369364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the time of initial relapse and subsequent relapses in patients with childhood-onset idiopathic nephrotic syndrome.
    Inoki Y; Nishi K; Osaka K; Kaneda T; Akiyama M; Sato M; Ogura M; Kamei K
    Pediatr Nephrol; 2024 Aug; 39(8):2393-2401. PubMed ID: 38267591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.
    Fribourg M; Cioni M; Ghiggeri G; Cantarelli C; Leventhal JS; Budge K; Bin S; Riella LV; Colucci M; Vivarelli M; Angeletti A; Perin L; Cravedi P
    Front Immunol; 2021; 12():726428. PubMed ID: 34621271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial.
    Hogan J; Perez A; Sellier-Leclerc AL; Vrillon I; Broux F; Nobili F; Harambat J; Bessenay L; Audard V; Faudeux C; Morin D; Pietrement C; Tellier S; Djeddi D; Eckart P; Lahoche A; Roussey-Kesler G; Ulinski T; Boyer O; Plaisier E; Cloarec S; Jolivot A; Guigonis V; Guilmin-Crepon S; Baudouin V; Dossier C; Deschênes G
    BMJ Open; 2020 Sep; 10(9):e037306. PubMed ID: 32967877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome.
    Colucci M; Angeletti A; Zotta F; Carsetti R; Lugani F; Ravà L; Ravani P; Emma F; Ghiggeri GM; Vivarelli M
    Kidney Int; 2023 Sep; 104(3):577-586. PubMed ID: 37385541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
    Iijima K; Sako M; Oba M; Tanaka S; Hamada R; Sakai T; Ohwada Y; Ninchoji T; Yamamura T; Machida H; Shima Y; Tanaka R; Kaito H; Araki Y; Morohashi T; Kumagai N; Gotoh Y; Ikezumi Y; Kubota T; Kamei K; Fujita N; Ohtsuka Y; Okamoto T; Yamada T; Tanaka E; Shimizu M; Horinochi T; Konishi A; Omori T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Nozu K;
    J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome.
    Sobue Y; Nishi K; Kamei K; Inoki Y; Osaka K; Kaneda T; Akiyama M; Sato M; Ogura M; Ishikura K; Ishiguro A; Ito S
    Pediatr Nephrol; 2024 Jun; 39(6):1825-1835. PubMed ID: 38270600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome.
    Bhatia D; Sinha A; Hari P; Sopory S; Saini S; Puraswani M; Saini H; Mitra DK; Bagga A
    Pediatr Res; 2018 Oct; 84(4):520-526. PubMed ID: 29983411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.